Invitrogen in $381m Dynal acquisition
Invitrogen has signed a definitive agreement to acquire Dynal from majority owner Nordic Capital and a co-investor for approximately US$381m.
Invitrogen has signed a definitive agreement to acquire Dynal from majority owner Nordic Capital and a co-investor for approximately US$381m.
Dynal is a specialist in biomagnetic separation techniques for isolation and manipulation of biological material, including cells, nucleic acids, proteins and pathogenic micro-organisms. The deal is expected to be completed by the end of the first quarter.